COL3A1 (Collagen Type III Alpha 1 Chain)

The results demonstrated the existence of a single regulatory axis, "TAMs - cytokines - ECM", which determined the development of the immunosuppressive and invasive BC microenvironment. The predominance of CD163+ Mj against the background of increased levels of IL-10, SPP1, and COX-2 was associated with a high degree of BC malignancy.

Importantly, quantitative polymerase chain reaction (qPCR) validation of selected hub genes confirmed significant upregulation of the extracellular matrix components COL1A1 and PXDN in EpCAM-overexpressing FLO-1 cells, supporting the transcriptomic predictions and implicating ECM remodeling as a downstream consequence of EpCAM signaling. Collectively, these findings demonstrate that EpCAM promotes aggressive cellular phenotypes in ESCA and drives transcriptional programs associated with adhesion, invasion, and extracellular matrix regulation, highlighting potential therapeutic vulnerabilities in EpCAM-driven ESCA.

Our findings establish COL3Ahigh CAFs as key mediators of resistance through metabolic symbiosis and immune evasion. The strong correlation between COL3Ahigh CAF abundance and clinical poor response highlights their potential as both predictive biomarkers and therapeutic targets to overcome chemoresistance in BC patients.

Targeting COL3A1 could significantly inhibit GC growth in vivo. Collectively, our findings indicated that COL3A1 could act as an oncogene in GC through regulating the PI3K-AKT signaling pathway.

AST treatment mitigated these fibrotic changes, as evidenced by reductions in gene expression (p=0.001 for COL1A1 and p=0.005 for COL3A1) and improvements in Masson's trichrome staining. In conclusion, this study suggests that AST may confer a protective effect against BPA-induced testicular damage by reducing apoptosis and fibrosis; however, changes in oxidative stress markers did not achieve statistical significance. Furthermore, AST may enhance spermatogenesis.

Mechanistically, IFN-γ and TNF-α synergistically promoted SMAD7 overexpression, which competitively bound to SMAD2/3 and suppressed TGF-β signaling, ultimately leading to ECM dysregulation. These data delineate a novel inflammatory axis impairing lung development, highlighting SMAD7 and TGF-β pathways as promising intervention targets.

MFAP2 overexpression was associated with upregulation of epithelial-to-mesenchymal transition-related genes. Overall, our results establish an extracellular signature and onco-architecture for the metaplastic triple-negative tumor type.

Although the pathway specificity and in vivo relevance require further studies, our findings provide evidence that PL-PN promotes extracellular matrix regeneration via coordinated proliferative, anabolic, and anti-inflammatory actions. Thus, PL-PN represents a potential sustainable plant-based alternative to S-PDRN for dermatological regeneration.

Ocriplasmin and pamidronate were identified as potential therapeutics. Our findings highlight the therapeutic relevance of these hub genes and identify them as potential drug targets and prognostic biomarkers in ovarian cancer.

ADAR1-imposed RNA editome suppresses HSC-intrinsic innate immunity and promotes collagen production, leading to aggravated HSC activation and liver fibrosis. Targeting ADAR1 with its pharmacological inhibitor or HSC-selective RNAi shows great promise in treating liver fibrosis.

Our findings suggest that the expression levels of serglycin, ILK, ESD, and PLPD1 may play a significant role in the development of LAC. This information can be valuable for identifying potential treatment targets for lung cancer.

High PD-L1 expression in BC tissue is associated with features of an immunosuppressive TME, including increased infiltration of immune cells with pro-tumorigenic properties, alterations in the cytokine profile, and remodeling of the stromal matrix.